to print the meeting flyer and registration form.
Does drug metabolism hold its future in its own hands?
Dr. Dennis Smith, Ph.D
Pfizer Academic Research Fellow
Dr Dennis Smith worked in the pharmaceutical industry for 32 years after gaining his Ph.D from the University of Manchester. For 20 years he was at Pfizer Global Research and Development, Sandwich where he was Vice President-Pharmacokinetics, Dynamics and Metabolism. For the past 2 years he has been a Pfizer Academic Research Fellow working on a part-time basis. His research interests and publications span all aspects of Drug Discovery and Development particularly where drug metabolism knowledge can impact on the design of more efficacious and safer drugs. During this 30-year span he has helped in the Discovery and Development of eight marketed NCEs. He has authored over 120 publications including two books. Recent publications include:
Schmid, Esther F; Ashkenazy R.; Merson, J; Smith Dennis A. Will biomedical innovation change the future of healthcare? Drug Discovery Today (in Press, available as preview)
Smith, Dennis A.; Dogma driven science, the need to establish a common base line. Chemico-Biological Interactions (2009), 179(1), 68-70.
Smith, Dennis A.; Obach, R. Scott; Williams, Dominic P.; Park, B. Kevin. Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity. Chemico-Biological Interactions (2009), 179(1), 60-67.
Smith, Dennis A.; Obach, R. Scott. Metabolites in Safety Testing (MIST): Considerations of Mechanisms of Toxicity with Dose, Abundance, and Duration of Treatment. Chemical Research in Toxicology (2009), 22(2), 267-279.
Fenner, Kath S.; Troutman, Matt D.; Kempshall, Sarah; Cook, Jack; Ware, Joe; Smith, Dennis A.; Lee, Caroline A. Drug–Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug. Clinical Pharmacology & Therapeutics(2008) 85, 173-181
Smith, Dennis A.; Jones, Rhys M. The sulfonamide group as a structural alert: a distorted story? Current Opinion in Drug Discovery & Development (2008), 11(1), 72-79.
He is active in a teaching role holding appointments as Visiting Professor at the University of Liverpool and Honorary Senior Lecturer at the University of Aberdeen and lectures widely to students at several other Universities.
His wish in his work now is to have fun in the science and “to inspire another generation to take up the cudgel against disease”.
||Tuesday April 27, 2010 – 5:00 p.m. (Buffet), 7:00 p.m. (Presentation)
||Jewish Community Center of San Diego
$20 Registration in advance or at the door (includes buffet dinner and soft drinks/beer/wine)
Space is Limited — Register Early to Guarantee Your Attendance!
|Dr. Paul F. Hollenberg
|| Mechanism-Based Inactivation of Human Cytochromes P450
||October 6, 2009
|Dr. Jack H. Dean
Dr. Thomas Baillie
| Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective
||May 19, 2009
|Eric Johnson, Ph.D.
|| Characterization of Substrate/Inhibitor Binding to Drug-Metabolizing Cytochrome P450 Monooxygenases using X-ray Crystallography
||September 30, 2008
|Dr. Kenneth E. Thummel, Ph.D.
|| Regulation Of Intestinal CYP3A By VDR: Implications And Safety Of Oral Therapeutics
||May 7, 2008
|Dr. Anthony Lu, Ph.D.
|| Why Is The Liver Microsomal Cytochrome P450 Such A Versatile And Unique Enzyme?
||September 12, 2007
|Dr. Scott Obach, Ph.D.
|| Leveraging ADME Data In Metabolites In Safety Testing (MIST)
||April 18, 2007
|Dr. Sidney Nelson, Ph.D.
|| Drug Metabolism and Chemical Structural Alerts
||September 27, 2006
|Richard B. Kim, MD
|| Relevance and Utility of Transporters to Drug Discovery and Development
||September 21, 2005
|Dr. Frederick P. Guengerich, Ph.D.
|| Human Cytochrome P450 2A6 as a Case History: Flavors, Smoke, Blue Roses, New Drugs & Basics of a P450
||April 27, 2005
|Dr. Leslie Benet, Ph.D.
||Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and BDDCS
||September 29, 2004
|Dr. Christopher A. Lipinski, Ph.D.
||ADME/Tox: How Low Can You Go And How Do You Recover?
||April 21, 2004
Our April 2010 meeting is generously sponsored by: